Is it safe?
Can BSX take a bad year?
Boston Scientific carries $12.1B of net debt at 2.32× EBITDA: a load its earnings can carry.
$12.1B
Net debt · as at Q2 2026 · under two and a half years of EBITDA, comfortable
- Net debt / EBITDA
- 2.32×
Net debt / EBITDA · 2.74× a year ago · the load is coming down
- Altman Z-score
- 3.07
Altman Z-score · safe zone, above 3
- Interest cover
- 11.4×
Interest cover · operating profit covers the interest bill several times over
Details›
- Total debtQ2 2026
- $12.6B
- Cash and short-term investments
- $539M
- Net debt
- $12.1B
- EBITDA, trailing twelve months
- $5.22B
- Operating profit, trailing twelve months
- $4.15B
- Debt / equity
- 0.50×
- Total debt / EBITDA
- 2.42×
- Annualised volatilitytwo years of daily moves
- 31%
- Worst drawdown on file
- −61%
- Below its 52-week high
- −55%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Medical Devices
Ranks #24 of 35 by Smart Score